高血压管理处于转折点:强化降压目标与新型机制的心血管预防
本综述总结近4年里程碑试验证实强化降压至收缩压<120 mm Hg可降低高危人群心血管事件与死亡,2025 AHA/ACC指南据此推荐<130/80 mm Hg目标并鼓励收缩压<120 mm Hg。同时新型药物与器械疗法激活内皮素、醛固酮合成、肝脏血管紧张素原及肾交感神经等通路,提出基于表型的精准管理框架。
要点
- 强化降压至收缩压<120 mm Hg可降低高危人群心血管事件与死亡。
- 2025 AHA/ACC指南推荐<130/80 mm Hg目标,可行时鼓励收缩压<120 mm Hg。
- 新型药物与器械疗法针对内皮素等通路,推动个体化精准管理。
核心结论
- 强化降压至收缩压<120 mm Hg可降低高危人群心血管事件与死亡,新型疗法开启精准管理时代。
研究设计与样本
- 综述综合近4年里程碑试验及2025 AHA/ACC高血压指南,并汇总新型药物与器械疗法机制。
主要发现
- 强化降压至收缩压<120 mm Hg可降低高危人群心血管事件与死亡。
- 2025 AHA/ACC指南推荐<130/80 mm Hg目标,可行时鼓励收缩压<120 mm Hg。
- 新型药物与器械疗法靶向内皮素、醛固酮合成、肝脏血管紧张素原及肾交感神经,结束>15年无新机制局面。
关键数值与推荐
- 2025 AHA/ACC指南推荐<130/80 mm Hg目标,可行时鼓励收缩压<120 mm Hg。
临床怎么用
- 采用更强化血压目标,并根据主导驱动因素选择新型药物或器械疗法实现个体化精准管理。
- 从一刀切阶梯治疗转向基于表型的精准管理。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Hypertension management is at an inflection point. Over the past 4 years, landmark trials have definitively established that intensive blood pressure (BP) lowering to systolic targets below 120 mm Hg reduces cardiovascular events and mortality across diverse high-risk populations, and the 2025 American Heart Association/American College of Cardiology (AHA/ACC) hypertension guideline has incorporated these findings into a universal <130/80 mm Hg goal with encouragement to achieve systolic BP <120 mm Hg when feasible. At the same time, novel pharmacological and device-based therapies have engaged mechanistic pathways previously left unopposed-endothelin, aldosterone biosynthesis, hepatic angiotensinogen, and renal sympathetic nerves-ending a >15-year drought in new antihypertensive mechanisms. This review synthesizes these converging developments and frames them within an emerging phenotype-driven framework that matches therapy to the dominant driver of uncontrolled or difficult-to-treat hypertension. The implications for cardiovascular disease prevention are substantial: more aggressive targets are now achievable through more precise therapies, and the coming years will require a shift from 1-size-fits-all stepped care toward individualized precision management.
引用
- Agarwal R. Hypertension at an Inflection Point: Aggressive Targets Meet Novel Mechanisms for Cardiovascular Prevention. J Am Coll Cardiol. 2026. PMID: 42307497. doi:10.1016/j.jacc.2026.05.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。